Evaluation of ciprofloxacin 500 mg twice daily for one week in treating uncomplicated gonococcal chlamydial, and non-specific urethritis in men.
Ciprofloxacin, a quinolone antibacterial, was evaluated in the treatment of gonococcal, chlamydial, gonococcal and chlamydial, and non-gonococcal non-chlamydial urethritis. The dosage regimen used was 500 mg orally twice a day for seven days. Of the 56 patients evaluated 22 had gonococcal infection only, 13 were infected with Chlamydia trachomatis only, seven had combined infection, and 14 were harbouring neither of these organisms. Neisseria gonorrhoeae was cleared in all the 29 patients with or without chlamydial infection. Of those who denied having sexual intercourse during the follow-up period, post gonococcal urethritis (PGU) developed in 12 (63%) out of 19, C trachomatis was isolated again from 11 (78%) out of 14, and urethritis recurred in five (55%) out of nine patients with non-gonococcal non-chlamydial infection. There was also evidence that the dosage regimen used was only partially effective against Ureaplasma urealyticum.
D000328:Adult; D002690:Chlamydia Infections / Q000188:drug therapy*; D002939:Ciprofloxacin; D004341:Drug Evaluation; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011804:Quinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D014526:Urethritis / Q000188:drug therapy*
D011804:Quinolines; D002939:Ciprofloxacin